Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, Juliana Pereira, Carlos Chiattone et al.|Journal of Clinical Oncology|2019

Cited by 154